Navigation Links
Helix BioPharma reports Q2 2008 highlights, financial results
Date:3/10/2008

ix month periods ended January 31, 2008, compared to $310,000 and $600,000, respectively, for the same periods last year. Margins, on percentage basis, have remained relatively stable in both the three and six month periods ended January 31, 2008, when compared to 2007.

Research & development

Research & development costs for the three and six month periods ended January 31, 2008, totaled $1,029,000 and $1,811,000, respectively, compared to $1,065,000 and $1,973,000, respectively, a year ago. In the three and six month periods ended January 31, 2008, research & development expenditures for both L-DOS47 and Topical Interferon Alpha2-b were less than in the same periods a year ago, with the majority of the lower research and development expenditures related to L-DOS47.

The reduction in research and development expenditures for L-DOS47 in the period were related to the various stages of completion associated with the multiple projects within the L-DOS47 program. Helix intends to seek approval in 2008 from the U.S. Food and Drug Administration ("FDA") for a Phase I clinical study in lung adenocarcinoma patients and, therefore, is currently advancing its L-DOS47 scale-up manufacturing program in anticipation of furnishing product for the clinical trial.

Research and development expenditures related to the Phase II trial in Sweden for ano-genital warts ("AGW") were more than offset by the reduction in costs associated with the Phase II study in Germany for women with precancerous, HPV induced low-grade cervical lesions.

The late-stage Phase II study in Germany was completed during the six month period ended January 31, 2007. Based on the positive findings, the Company is currently developing plans for a large, randomized, placebo-controlled double-blind study to evaluate the product in an expanded patient population in addition to preparatory work in anticipation of Investigational New Drug ("IND") and Clinical Trial Application ("CTA") f
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Due to a misstatement posted by the ... Cell Technology Center, LLC ( ASCTC ) was reported as ... that might benefit ALS patients. Because of ASCTC's exclusive ... technologies and therapeutic applications, FRC listed ASCTC as one of ... who wish not to support research that requires the death ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., a ... food processing industry, is asking industry professionals to prepare ... of the E2 soap they’re currently using to the ... . Hand hygiene is critical to fighting cross-contamination ... environment. Six key criteria are identified to evaluate the ...
(Date:8/28/2014)... devices in spintronics, an electronic which is not ... also on their spin and the spin-related magnetism. ... magnetic signals and vice versa. Recently, the research ... of Physics at Johannes Gutenberg University Mainz in ... Japan, has for the first time realised a ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2A new, tunable device for spintronics 2A new, tunable device for spintronics 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
(Date:8/28/2014)... at the University of Minnesota have developed an animal ... used for muscle regeneration research as well as studies ... The research is published in the current edition of ... no treatment for FSHD, which is thought by many ... FSHD is an unusual genetic disorder because, unlike most ...
(Date:8/28/2014)... compounds that could positively impact the global ... possible, thanks to researchers in Penn State,s ... suppository made from the seaweed-derived food ingredient ... Tenofovir provides a woman-initiated, drug-delivery vehicle that ... transmitted infections during unprotected heterosexual intercourse, the ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Hamilton, Nov. 11, 2013 Researchers at McMaster University have ... and it may serve as a way to measure injury. ... muscle damage biomarker," said Thomas Hawke, principal investigator and an ... at McMaster. "Regardless of the way in which ...
... after giving birth plays a big factor in the quantity and ... University of Missouri have found that subclinical hypocalcemia, which is the ... occurs in many cows after giving birth, is related to higher ... the MU College of Veterinary Medicine, says these higher levels of ...
... his sons less sensitive to the drug and thereby more ... animal study presented by Penn Medicine researchers at Neuroscience 2013, ... The study, led by Mathieu Wimmer, PhD, a post-doctoral researcher ... of Neuroscience in Psychiatry at the Perelman School of Medicine ...
Cached Biology News:Low levels of blood calcium in dairy cows may affect cow health and productivity, MU study finds 2Sons of cocaine-using fathers may resist addiction to drug, Penn Medicine study suggests 2
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... brings together two mature, well-understood technologies: ... surfaces. This combination produces a sensitive ... detection of molecular binding events without ... Protein-specific capture molecules are immobilized on ...
... LabWorks Software provides a comprehensive experiment based ... drop down menus yet sophisticated and powerful ... dozens of CCD cameras for easy image ... , Automated Digital Video Playback ...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
Biology Products: